Detail akcie Biomarin Pharma online

Business Summary: BioMarin Pharmaceutical Inc. (BioMarin) is a global biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Biomarin Pharmaceutical Inc revenues increased 15% to $745.1M. Net income increased from $88.7M to $185.7M. Revenues reflect Voxzogo segment increase of 40% to $213.8M, Palynziq1 segment increase of 23% to $93.3M, United States segment increase of 25% to $241.7M, Rest of the world segment increase of 61% to $126.1M.